Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients

Table 1

Advanced melanoma patients’ characteristics before ACT.

Patient	Sex	At diagnosis			Advanced or metastatic disease		Treatments before TILs			BRAF	c-KIT
		Localization	Breslow (mm)	AJCC Stage	Age	Metastasis diagnosis to TIL injection (years)	Chemotherapy	Anti-CTLA4; (ipilimumab to TILs time, months)	Others	Status	Status
1	F	Scalp	3	II	15	1.6	Fote	Ipilimumab [16]	RT, Surg	WT	WT
2	F	Left ankle	2	NA	36	1.6	DCB	BMS^a [17]		V600E	WT
3	F	Back	5	II	68	2.4	DCB, carbo, cycloP	BMS^a [27]		V600E	WT
4	F	Back	5.2	II	59	5.3	DCB, carbo, vind, temo		Vac	V600E	WT
5	F	Left leg	1.21	NA	38	2.5	DCB, carbo, paclitaxel		RT	NA	WT
6	F	Left foot	2.85	II	76	0.1	None	None	None	V600E	WT
7	F	Left leg	0.74	I	62	10.1	DCB, carbo		Vac, AZD	WT	Mutated
8	M	Right foot	5.75	II	87	0.8	DCB, temo	Ipilimumab [5]	Vac	WT	WT
9	F	Left leg	1.85	I	82	0.9	DCB			WT	WT
10	F	Right leg	3	II	63	10.75			Vac	WT	WT

AJCC: American Joint Committee on Cancer; AZD: NCT00338130 study (AstraZeneca AZD 6244 versus temo); BMS: study (dacarbazine + ipilimumab 10 mg/kg versus dacarbazine + placebo); carbo: carboplatin; cycloP: cyclophosphamide; DCB: dacarbazine; Fote: fotemustine; NA: data not available; RT: radiotherapy; Surg: surgery; temo: temozolomide; Vac: vaccination; vind: vindesine; WT: wild type. ^aPatient in the dacarbazine + ipi arm.